10.1155/2016/1737185 203 ZhangC.SongY.ChenL.ChenP.YuanM.MengY.et al (2022a)
The design bet behind a GLP-1/glucagon dual agonist is that GLP-1s insulinotropic, appetite-suppressing, glucose-lowering effects can be used to offset the hyperglycemic tendency of glucagon, while glucagons thermogenic and hepatic-lipid effects add weight-loss and liver-directed benefits that GLP-1 alone does not deliver
Enhanced Mobility for Weight Loss By improving joint function and reducing pain, AOD-9604 can help users increase physical activity, creating a positive feedback loop for accelerated fat loss, cardiovascular health, and mental well-being
Andrews, Ronald Wetzel, Human Molecular Genetics, Volume 11, Issue 23, 1 November 2002, Pages 29052917
Therefore, precise and prompt clinical diagnosis holds paramount importance